Author

E. Yaaghubi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Organism:mouse· 1

Frequent Co-Authors

B. J. Davis· 2 shared B. K. Law· 2 shared C. D. Heldermon· 2 shared C.-W. Chiang· 2 shared M. E. Law· 2 shared M. Wang· 2 shared O. Guryanova· 2 shared R. K. Castellano· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. J. Davis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Repurposing Tranexamic Acid as an Anticancer Agent

M. E. Law, B. J. Davis, A. F. Ghilardi, E. Yaaghubi, Z. M. Dulloo, M. Wang, O. Guryanova, C. D. Heldermon, R. K. Castellano, B. K. Law

This study shows Tranexamic Acid inhibits cancer growth by blocking Plasmin-mediated CDCP1 cleavage and disrupts multiple intracellular signaling pathways.

bioRxiv · Oct 17, 2021 · PreprintCancer Biology

Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death

M. E. Law, E. Yaaghubi, A. Ghilardi, B. J. Davis, R. B. Ferreira, J. Koh, S. Chen, S. F. DePeter, C. M. Schilson, C.-W. Chiang, C. D. Heldermon, P. Norgaard, R. K. Castellano, B. K. Law

This study identifies DDAs as inhibitors of AGR2 and ERp44, showing they induce DR4/5 oligomerization and cancer cell death via disrupting disulfide bonds.

bioRxiv · Jan 13, 2021Pharmacology & Toxicology

Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator

M. Wang, M. Law, B. Davis, E. Yaaghubi, A. Franceschini Ghilardi, R. Ferreira, C.-W. Chiang, O. Guryanova, D. Kopinke, C. Heldermon, R. Castellano, B. Law

This study identifies DDAs as compounds that upregulate DR5 in cancer cells, leading to apoptosis and synergy with TRAIL, with selectivity for oncogene-transformed cells.

bioRxiv · Jul 14, 2019 · PreprintCancer Biology